Article
PODCAST: DHP Villains: Woodrow Wilson, Part 10
aboutLiberty Portal
Liberty Portal is your gateway for free markets and free thinking. We aggregate open-sourced content to promote and popularize important people and lessons within the liberty movement.
suggested
Feb 19, 2026 / Tyler Durden
Iran Will Be "Finding Out" Over Next 10 Days, Trump Says, But Asserts "Good Talks"
Iran Will Be "Finding Out" Over Next 10 Days, Trump Says, But Asserts "Good Talks"
Update(1021ET): As has become typical, President Trump is all over the place - his intentions ever more difficult to interpret - at a moment the media has highlighted Iraq war levels of military build-up in the Middle East with an eye on potential attack on Iran.
On Thursday he oversaw the inaugural meeting in Washington DC of the Board of Peace related to Gaza. In televised remarks he surprisingly called tense negotiations with Iran "good talks". But then he...
Read more
Feb 14, 2026 / Tyler Durden
More Nations Are Mulling Social Media Bans For Teens
More Nations Are Mulling Social Media Bans For Teens
After Australia's first-of-its-kind social media ban for adolescents under the age of 16 came into effect in December, more countries in Europe and elsewhere are taking steps to implement their own restrictions.
As Katharina Buchholz reports, according to Statista research, France and the United Kingdom have gotten furthest, with laws passing in one chamber each of the countries' bicameral legislatures as of early February. While the latter country is also aiming to ban social media for kids under the age of 16, France's...
Read more
Feb 23, 2026 / Tyler Durden
"Worst-Case Scenario": Novo Nordisk Plunges After Next-Gen Obesity Drug Falls Short Of Lilly Rival
"Worst-Case Scenario": Novo Nordisk Plunges After Next-Gen Obesity Drug Falls Short Of Lilly Rival
Shares of Novo Nordisk A/S plummeted again on Monday after the company reported trial results showing its next-generation obesity shot, CagriSema, delivered 20.2% weight loss at 84 weeks, compared to 23.6% for Eli Lilly & Co.’s tirzepatide (Zepbound).
Bloomberg Intelligence analyst Michael Shah explained, "This outcome is the worst-case scenario for Novo and heightens the need for M&A with Novo’s other GLP-1/Amylin drug."
Shares of Novo in Copenhagen plunged as much as 16.5%, breaking below a support level...
Read more


